Home › Funds › Venrock Adviser, LLC › APGE
Venrock Adviser, LLC position in APGE
APOGEE THERAPEUTICS INC
Venrock Adviser, LLC reported holding 8,493,321 shares of APGE (APOGEE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$1.13B, representing 34.18% of its reported portfolio and ranking #1 among its reported holdings. Venrock Adviser, LLC has disclosed APGE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's APGE position evolved
Venrock Adviser, LLC first disclosed a stake in APGE in Q3 2023 at 8,493,321 shares (US$180.9M). The position peaked in Q2 2026 at 8,493,321 shares, worth US$1.13B. Across 12 filings, Venrock Adviser, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 8,493,321 shares valued at US$1.13B.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 8.49M | $180.91M | New |
| Q4 2023 | 8.49M | $237.30M | Hold |
| Q1 2024 | 8.49M | $564.38M | Hold |
| Q2 2024 | 8.49M | $334.21M | Hold |
| Q3 2024 | 8.49M | $498.90M | Hold |
| Q4 2024 | 8.49M | $384.75M | Hold |
| Q1 2025 | 8.49M | $317.31M | Hold |
| Q2 2025 | 8.49M | $368.86M | Hold |
| Q3 2025 | 8.49M | $337.44M | Hold |
| Q4 2025 | 8.49M | $641.08M | Hold |
| Q1 2026 | 8.49M | $714.88M | Hold |
| Q2 2026 | 8.49M | $1.13B | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About APGE and 13F data
APGE (APOGEE THERAPEUTICS INC) is a company whose sector is not yet classified in our data. 59 other funds we track also report a position in APGE — the largest reported positions include HBK INVESTMENTS L P (US$378.3M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$231.0M), GLAZER CAPITAL, LLC (US$217.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding APGE
- HBK INVESTMENTS L P 2.85M sh · $378.28M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.74M sh · $230.96M · Q2 2026
- GLAZER CAPITAL, LLC 1.64M sh · $217.82M · Q2 2026
- Paradigm Biocapital Advisors LP 1.58M sh · $209.23M · Q2 2026
- Pentwater Capital Management LP 1.43M sh · $189.14M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.31M sh · $173.63M · Q2 2026
- Affinity Asset Advisors, LLC 987.00K sh · $131.00M · Q2 2026
- First Light Asset Management, LLC 930.29K sh · $123.48M · Q2 2026
- Kryger Capital LLC 742.55K sh · $98.56M · Q2 2026
- First Trust Capital Management L.P. 625.18K sh · $82.98M · Q2 2026
- Remedium Capital Partners, LLC 586.69K sh · $77.87M · Q2 2026
- Soros Fund Management 564.50K sh · $74.93M · Q2 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held APGE?
Venrock Adviser, LLC has disclosed APGE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Venrock Adviser, LLC's current position in APGE?
As of Q2 2026, Venrock Adviser, LLC holds 8.49M shares of APGE (APOGEE THERAPEUTICS INC), valued at $1.13B, representing 34.18% of its reported portfolio and ranking #1.
Has Venrock Adviser, LLC been buying or selling APGE?
In the latest 13F filing (Q2 2026), Venrock Adviser, LLC held unchanged its position in APGE. The position peaked in Q2 2026 at 8.49M shares.
Which other funds hold APGE?
Other major institutional holders of APGE include HBK INVESTMENTS L P, DRIEHAUS CAPITAL MANAGEMENT LLC, GLAZER CAPITAL, LLC, among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.